Scarica l'app Stockscreener
16.06
0.86%
-0.14
Dopo l'orario di chiusura:
15.94
-0.12
-0.75%
Precedente Chiudi:
$16.20
Aprire:
$16.28
Volume 24 ore:
2.69M
Relative Volume:
1.20
Capitalizzazione di mercato:
$1.38B
Reddito:
$139.71M
Utile/perdita netta:
$-209.36M
Rapporto P/E:
-5.4257
EPS:
-2.96
Flusso di cassa netto:
$-160.60M
1 W Prestazione:
+2.95%
1M Prestazione:
+2.10%
6M Prestazione:
+52.66%
1 anno Prestazione:
-11.76%
Intervallo 1D:
$15.41
$16.48
Intervallo di 1 settimana:
$15.41
$16.80
Portata 52W:
$8.58
$22.50
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Nome
Syndax Pharmaceuticals Inc
Settore
Industria
Telefono
781-419-1400
Indirizzo
730 THIRD AVENUE, NEW YORK, MA
Confronta SNDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
16.06 | 1.40B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-10 | Ripresa | Stifel | Buy |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-08-05 | Reiterato | BTIG Research | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-06-28 | Iniziato | Jefferies | Buy |
| 2024-01-31 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-10-25 | Iniziato | BofA Securities | Buy |
| 2023-10-11 | Iniziato | Goldman | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-11 | Iniziato | Guggenheim | Buy |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2023-01-03 | Iniziato | JP Morgan | Overweight |
| 2022-07-28 | Ripresa | B. Riley Securities | Buy |
| 2022-04-11 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-15 | Iniziato | Goldman | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-25 | Iniziato | Citigroup | Buy |
| 2021-02-18 | Iniziato | B. Riley Securities | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Downgrade | Citigroup | Buy → Neutral |
| 2020-05-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-01-04 | Iniziato | Robert W. Baird | Outperform |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Iniziato | FBR & Co. | Outperform |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2016-10-07 | Iniziato | Guggenheim | Buy |
| 2016-03-28 | Iniziato | Citigroup | Buy |
| 2016-03-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-03-28 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie
Evaluating Syndax Pharmaceuticals Inc. with trendline analysis2025 Pullback Review & Reliable Price Breakout Alerts - newser.com
Will Syndax Pharmaceuticals Inc. stock see insider buying2025 EndofYear Setup & Verified Chart Pattern Signals - newser.com
Published on: 2025-10-10 04:00:50 - newser.com
Menin Inhibitors Drug Market Report 2025: Price, Sales & Clinical Trials Insights 2024-2028 - GlobeNewswire Inc.
Order flow analysis tools used on Syndax Pharmaceuticals Inc.2025 Retail Activity & Fast Gain Swing Trade Alerts - newser.com
Syndax resumed with Buy at Stifel on newly launched drugs - MSN
Analyzing drawdowns of Syndax Pharmaceuticals Inc. with statistical toolsPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Published on: 2025-10-09 05:04:06 - newser.com
Should you hold or exit Syndax Pharmaceuticals Inc. nowJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Is Syndax Pharmaceuticals Inc 1T3 a good long term investmentValue Traps to Avoid & Small Investment Portfolio - earlytimes.in
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - AOL.com
Technical analysis overview for Syndax Pharmaceuticals Inc. stockJuly 2025 Trends & AI Driven Price Forecasts - newser.com
Research Analysts Offer Predictions for SNDX FY2027 Earnings - MarketBeat
Will October's FDA Decision Be A Shot In The Arm For Revuforj's Expansion? - RTTNews
Is Syndax Pharmaceuticals Inc. (1T3) stock considered safe havenJuly 2025 Rallies & Short-Term High Return Strategies - newser.com
Measuring Syndax Pharmaceuticals Inc.’s beta against major indices2025 Geopolitical Influence & Reliable Volume Spike Alerts - newser.com
Comparing Syndax Pharmaceuticals Inc. in custom built stock radarsProduct Launch & Real-Time Volume Analysis Alerts - newser.com
Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision - Yahoo
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
BRIEF-Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - The Sunday Guardian
Syndax Pharmaceuticals reports inducement grants under Nasdaq Listing Rule - MarketScreener
Does Syndax Pharmaceuticals Inc. qualify in momentum factor screeningStop Loss & Daily Entry Point Trade Alerts - newser.com
138,900-Share Grant: Syndax Awards to 10 New Employees; Options Vest Monthly Under Inducement Plan - Stock Titan
Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals - MSN
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
What analysts say about Syndax Pharmaceuticals Inc stockEarnings Revision Updates & Minimize Portfolio Damage with Warnings - earlytimes.in
When Will Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Turn A Profit? - Yahoo Finance
Syndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from BTIG Research - MarketBeat
Risk On: Can Syndax Pharmaceuticals Inc stock double in the next yearGap Down & Real-Time Buy Zone Alerts - خودرو بانک
Multiple Insiders Sold Syndax Pharmaceuticals Shares Presenting Weak Signs For Investors - 富途牛牛
Syndax Pharmaceuticals Nears Critical Regulatory Milestone - AD HOC NEWS
Highs Report: What’s next for IRIDEX Corporation stockBreakout Watch & Daily Profit Focused Stock Screening - khodrobank.com
Update Recap: Can CZWI disrupt its industryEarnings Recap Report & Verified Entry Point Signals - khodrobank.com
BTIG Reiterates Buy Rating on SNDX with $56 Price Target | SNDX Stock News - GuruFocus
3 Potential Biotech Acquisition Targets - Seeking Alpha
SNDX: Revumenib Gains Key NCCN Recommendation for AML Treatment - GuruFocus
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia - The Manila Times
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical - GlobeNewswire
Syndax Pharmaceuticals Inc Azioni (SNDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Syndax Pharmaceuticals Inc Azioni (SNDX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Metzger Michael A | Chief Executive Officer |
Sep 08 '25 |
Sale |
16.41 |
157,307 |
2,582,021 |
298,661 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):